Schematic diagram of the active comparator new-user design comparing... | Download Scientific Diagram
Two-armed active comparator trials are unethical in pediatric multiple sclerosis – Yes - Lauren B Krupp, Leigh Elkins Charvet, 2020
Most noninferiority trials were not designed to preserve active comparator treatment effects - ScienceDirect
Empagliflozin monotherapy with sitagliptin as an active comparator in patients with type 2 diabetes: a randomised, double-blind, placebo-controlled, phase 3 trial - The Lancet Diabetes & Endocrinology
Dr. Theo's Official Website
001-006) Primeras 30-1(NUEVA)_(115-118) Primeras 25.3
Active-comparator arm - RaDaR
Comparative Effectiveness Clinical Trials in Psychiatry: Superiority, Noninferiority, and the Role of Active Comparators | Psychiatrist.com
Bimekizumab versus ustekinumab for the treatment of moderate to severe plaque psoriasis (BE VIVID): efficacy and safety from a 52-week, multicentre, double-blind, active comparator and placebo controlled phase 3 trial - The
Active-comparator design and new-user design in observational studies. - Abstract - Europe PMC
New‐user and prevalent‐user designs and the definition of study time origin in pharmacoepidemiology: A review of reporting practices - Luijken - 2021 - Pharmacoepidemiology and Drug Safety - Wiley Online Library
Clinical trial designs of new medicinal products for treating schizophrenia: discussion of EMA's Guideline and a Better Long Term Trial Design
Risankizumab compared with adalimumab in patients with moderate-to-severe plaque psoriasis (IMMvent): a randomised, double-blind, active-comparator-controlled phase 3 trial - The Lancet
Active-comparator design and new-user design in observational studies. - Abstract - Europe PMC
Is it ethical to use teriflunomide as an active comparator in phase 3 trials? - ScienceDirect
Clinical trial designs of new medicinal products for treating schizophrenia: discussion of EMA's Guideline and a Better Long Term Trial Design
SOLAR: A PHASE 2, GLOBAL, RANDOMIZED, ACTIVE COMPARATOR STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF COBOMARSEN IN SUBJECTS WITH MYCOSIS FUNGOIDES (MF) - James - 2019 - Hematological Oncology - Wiley Online Library
Is it ethical to use teriflunomide as an active comparator in phase 3 trials?
GitHub - OHDSI/ComparatorSelectionExplorer: This package is designed to aid the selection of comparators in active comparator, new user cohort designs by computing a similarity metric across all possible pairs of drug comparators
Active Control / Active Comparator - Statistics How To
A Phase 2a, randomized, active-comparator-controlled, open-label study to evaluate the efficacy and safety of efinopegdutide in individuals with nonalcoholic fatty liver disease
